Cemdisiran
RNA / oligonucleotide
Evidence outlook
Approved: generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor... (FDA, 2026-11-18)
FDA approves Livsayis (cemdisiran) for gMG. The approval is on record as a sourced regulatory event; the application record has not been loaded yet. Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Latest reported trial: NIMBLE (NCT05070858) · Phase 3 · met primary endpoint · grade pending
Also in development:Age-Related Macular Degeneration · Phase 3Generalized Myasthenia Gravis · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NIMBLE NCT05070858 · Myasthenia Gravis Registry: NCT05070858 | 3 | Change in Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score (From baseline to week 24) 2025-07-08 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Competitive landscape
Other Complement C5 drugs
Avacincaptad pegol, Eculizumab, Ravulizumab, Gefurulimab, Pozelimab and 1 more. Compare all 7 Complement C5 drugs
6 other tracked programmes target this mechanism, 3 of them ahead of this one.
This drug's own stage for Myasthenia Gravis: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Cemdisiran: this drug | Phase 3 | RNA / oligonucleotide | Complement C5 | not yet graded | No reviewed efficacy summary in this indication | |
| Eculizumab (Soliris) | Approved | Monoclonal antibody | Complement C5 | Partial signal | NCT01997229: Myasthenia Gravis Activities of Daily Living Profile (MG-ADL): Change From Baseline in MG-ADL Total Score at Week 26 by Worst-Rank Analysis of Covariance (ANCOVA) (End of study (Week 26)): Eculizumab 56.6 scores on a scale (Standard Error 4.53) | Placebo 68.3 scores on a scale (Standard Error 4.49) missed | |
| Efgartigimod Alfa (Vyvgart) | Approved | Antibody fragment | FcRn | not yet graded | No reviewed efficacy summary in this indication | |
| Ravulizumab (Ultomiris) | Approved | Monoclonal antibody | Complement C5 | not yet graded | No reviewed efficacy summary in this indication | |
| Descartes-08 | Phase 3 | Cell therapy | BCMA (B-cell maturation antigen) | not yet graded | No reviewed efficacy summary in this indication | |
| Imeroprubart | Phase 3 | Monoclonal antibody | FcRn | not yet graded | No reviewed efficacy summary in this indication | |
| Povetacicept | Phase 2 | Protein / enzyme therapeutic | BAFF / APRIL | not yet graded | No reviewed efficacy summary in this indication | |
| Ublituximab (Briumvi) | Phase 2 | Monoclonal antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Cemdisiran to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
May 2027 (1)
What to watch
2028 (2)
2030 (1)
January 2030 (1)
What to watch
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent